{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schardt JS"],"funding":["U.S. Department of Health &amp;amp; Human Services | National Institutes of Health","U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)","NIA NIH HHS","U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Albert M. Mattocks Chair, Biointerfaces Institute","University of Michigan Institutional Funds","National Science Foundation (NSF)","COVID-19: CVC Impact Research Ignitor Grant AwardUniversity of Michigan MICHR Accelerating Synergy Award","MICHR Education PTSP 2020","NSF Graduate Research Fellowship","U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)","U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of General Medical Sciences","NIGMS NIH HHS","National Science Foundation"],"pagination":["20738"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8528929"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide range of biomedical applications involving novel coronavirus disease (COVID-19) diagnosis, treatment, and prophylactic intervention. Strategies for the rapid and reliable isolation of these antibodies, especially potent neutralizing antibodies, are critical toward improved COVID-19 response and informed future response to emergent infectious diseases. In this study, single B cell screening was used to interrogate antibody repertoires of immunized mice and isolate antigen-specific IgG1<sup>+</sup> memory B cells. Using these methods, high-affinity, potent neutralizing antibodies were identified that target the receptor-binding domain of SARS-CoV-2. Further engineering of the identified molecules to incre"],"journal":["Scientific reports"],"pubmed_title":["Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening."],"pmcid":["PMC8528929"],"funding_grant_id":["R35 GM136300","1159943","F32 GM137513","RF1AG059723","R01 AI 51588 01","1813963","1605266","RF1 AG059723","R01 AI051588","R35GM136300"],"pubmed_authors":["Lanigan TM","Zupancic JM","Makowski EK","Garcia de Mattos Barbosa M","Tessier PM","Moon JJ","Chen H","Schardt JS","Park KS","Desai AA","Pornnoppadol G","Cascalho M","Smith MD"],"additional_accession":[]},"is_claimable":false,"name":"Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening.","description":"Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide range of biomedical applications involving novel coronavirus disease (COVID-19) diagnosis, treatment, and prophylactic intervention. Strategies for the rapid and reliable isolation of these antibodies, especially potent neutralizing antibodies, are critical toward improved COVID-19 response and informed future response to emergent infectious diseases. In this study, single B cell screening was used to interrogate antibody repertoires of immunized mice and isolate antigen-specific IgG1<sup>+</sup> memory B cells. Using these methods, high-affinity, potent neutralizing antibodies were identified that target the receptor-binding domain of SARS-CoV-2. Further engineering of the identified molecules to incre","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-04T09:18:39.07Z","creation":"2025-04-04T09:18:39.07Z"},"accession":"S-EPMC8528929","cross_references":{"pubmed":["34671080"],"doi":["10.1038/s41598-021-99401-x"]}}